Meet with... Johnson & Johnson Innovation
Meet with... Johnson & Johnson Innovation
Yale School of Medicine , Cohen Auditorium, NIHB E 02 , New Haven , Connecticut
April 21, 2016 from 12:30 PM to 14:30 PM (EST)
$10 - $35
How can Johnson & Johnson Innovation help you reach your goals? Johnson & Johnson Innovation (JJI) is supporting innovation in major life science clusters through the life science incubator, Johnson & Johnson Innovation, JLABS (JLABS), with the ultimate aim of enabling commercialization of new healthcare solutions for patients. We know what you, the innovator, need to get your science to patients. It is because of you that JJI created regional centers that host a team of science and transaction experts whose goal is to find high potential early-stage (pre-clinical proof-of-concept) innovation and form custom business solutions around it to help accelerate the science to the patient. The JJI team has broad deal-making capabilities with the flexibility to adapt the deal structures to the science.
On April 21, hear from Johnson & Johnson Innovation leaders as they provide an overview of J&J Innovation goals and mission, highlighting how J&J Innovation interacts with the entrepreneurial community through JLABS, JJDC, and other J&J Innovation initiatives.
Speakers will also be on hand to meet with a handful of applicants one-on-one after the presentation.
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
12:00pm | Networking Lunch
12:30-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be approved. The application period ended on March 21st.
Johnson & Johnson Innovation Participating Representatives:
Kuldeep Neote | Senior Director, New Ventures, J&J Innovation read bio»
Bob Radinsky | Vice President, Oncology Scientific Innovation, Janssen R&D, LLC read bio»
Ibraheem Badejo | Senior Director, New Ventures, J&J Innovation read bio»
This event is produced in partnership with CURE: Connecticut's Bioscience Innovation Network, The Yale Entrepreneurial Institute, and the Yale Office of Cooperative Research.
Presentation & Lunch
FREE | Academic
FREE | CURE Members
FREE | General Public
FREE | At the door
Includes presentation, Q&A, and lunch. All attendees must register, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on April 20th (or sold out).
FREE | Application
FREE | Accepted Companies
*Companies must have applied for a one-on-one meeting ahead of time. The one-on-one application period ended on March 21st. Your application will be reviewed and you will be notified of acceptance on April 4th. Acceptance of one-on-one meetings is not guaranteed as all applications must be approved.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, Poliwogg, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
Yale School of Medicine
Cohen Auditorium, NIHB E 02
230 South Frontage Road
New Haven, Connecticut
Johnson & Johnson Innovation Participating Representatives' Biographies:
Kuldeep Neote, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation, Boston
Kuldeep is Senior Director of New Ventures at the Johnson & Johnson Innovation, Boston. He focuses primarily on the areas of Oncology and Immunology. A trained molecular biologist with an extensive background in drug discovery, Kuldeep has been focused on the areas of Immunology, Inflammation and Oncology and has a passion for implementing cutting edge scientific discoveries into practical drug discovery programs. Formerly, Kuldeep was Research Advisor/Director in Global External R&D at Eli Lilly. Prior to Eli Lilly, he was a Discovery Scientist at Pfizer, where he initiated the chemokine receptor drug discovery platform that led to the discovery and further development of several clinical candidates. Earlier in his career, Kuldeep also cloned one of the first chemokine receptors while at Genentech. Kuldeep earned his BSc. in Microbial and Cellular Biology at the University of Calgary, and a Ph.D. in Human and Molecule Genetics at the University of Toronto, where he was a major contributor in the understanding of the molecular basis of lysosomal storage diseases, in particular Tay Sachs and Sandhoff's disease.
Connect with Kuldeep:
Robert Radinsky, Ph.D. | Vice President, Oncology Scientific Innovation, The Janssen Pharmaceutical Companies of Johnson & Johnson
Robert Radinsky, Ph.D. is Vice President, Scientific Innovation at Janssen Research & Development, LLC. He represents the Oncology Therapeutic Area in Johnson & Johnson Innovation, Boston. In this role, he is responsible for identifying and fostering innovation in the region that supports the Oncology Therapeutic Area strategies. Prior to this role, he led Discovery Research, Oncology, for Janssen. Robert has had a very successful oncology research career in both academics and industry. Prior to joining Janssen, he was Executive Director, Oncology Research at Amgen Inc., where he led groups at multiple research sites including Thousand Oaks, California, and Cambridge, Massachusetts. He was responsible, in part, for research and/or pharmacology for numerous active targeted therapeutic anti-cancer programs (protein, small molecule and nanotechnology modalities), culminating with multiple candidates in clinical trials and an approved drug for the treatment of colorectal carcinoma. Before joining the industry 14 years ago, Robert was on the faculty at The University of Texas MD Anderson Cancer Center in Houston, first serving as an American Cancer Society Postdoctoral Research Fellow in the Department of Cell Biology, and eventually becoming a tenured Associate Professor in the Department of Cancer Biology. He continued as an Adjunct Professor at the MD Anderson Cancer Center after joining the industry. Robert has published more than 130 peer-reviewed articles, holds multiple patents, and is a present/past member of numerous societies, including the American Association for Cancer Research, Board of Directors for the Metastasis Research Society, the American Association for the Advancement of Science, the Scientific Advisory Board and the Aspen Cancer Conference. He is an Editorial Member and/or ad hoc reviewer for more than 20 scientific journals and has served on review panels for a number of granting agencies, including the National Institutes of Health/National Cancer Institute, the Department of Defense Prostate and Breast Cancer Research Programs, and the Veterans Administration Merit Review Board. Robert earned his doctorate in Molecular Biology and Microbiology from Case Western Reserve University School of Medicine in Cleveland, Ohio.
Connect with Bob:
Ibraheem Badejo, Ph.D. | Senior Director, New Ventures, Johnson & Johnson Innovation, Boston
Ibraheem (Ib) is Senior Director, New Ventures at Johnson & Johnson Innovation, Boston. He leverages his expertise in smart materials and biomaterials to support the medical device sector. From 2010 to 2013, Ib was a Research Fellow at Global Surgery Group of Johnson & Johnson, where he was responsible for external and front-end innovations and intellectual property for Ethicon Biosurgery. From 2006 to 2010, he was the Director of Applied Research & New Technology Assessment of novel biomaterials. Prior to that, he was the Chief Scientist of Closure Medical Corp (acquired by J&J in 2005). Prior to joining Closure, he held various positions at Bayer, North Carolina State University, College of Charleston. He currently serves as an Adjunct Professor of Biomedical Engineering at Drexel University. During his career, Ib has led teams in the development of commercialized biomaterials based products and new technology / products licensed or acquired. Ib received his BA degree in chemistry from Avila University. He received his PhD in Organic chemistry from the University of Toledo, where he was the Robert Whiteford Memorial Scholar for Outstanding Graduate Research and a Petroleum Research Fund Fellow. He is also the recipient of 24 US patents with others pending.
Connect with Ibraheem: